(CS) AXA - Overview
Sector: Financial ServicesIndustry: Insurance - Diversified | Exchange PA (France) | Currency EUR | Market Cap: 91.539m | Total Return -0.3% in 12m
Stock: Insurance, Investments, Banking, Protection
Total Rating 39
Risk 48
Buy Signal -0.54
| Risk 5d forecast | |
|---|---|
| Volatility | 18.1% |
| Relative Tail Risk | 3.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.09 |
| Alpha | -3.26 |
| Character TTM | |
|---|---|
| Beta | 0.038 |
| Beta Downside | -0.350 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.69% |
| CAGR/Max DD | 1.14 |
Description: CS AXA March 05, 2026
AXA SA is a French multinational insurance and asset management firm. The company operates globally, providing a diverse range of insurance products including life, savings, property, and casualty.
AXAs business model is diversified across six segments, including France, Europe, AXA XL (commercial lines), Asia, Africa & EME-LATAM, and AXA Investment Managers. This structure allows for broad geographic reach and specialized services in areas like reinsurance and asset management. The insurance sector is characterized by long-term liabilities and significant regulatory oversight.
The company also offers banking services and a variety of specialized solutions such as parametric insurance and integrated health ecosystems. Asset management services cover various asset classes and multi-manager solutions, a common practice in the investment industry to diversify risk and expertise. Investors should consider further research on ValueRay for a deeper understanding of AXAs financial performance and market position.
Headlines to watch out for
- Global interest rate hikes boost investment income
- Catastrophe claims increase property and casualty payouts
- Regulatory changes impact insurance product offerings
- Emerging market growth drives new policy sales
- Asset management fees fluctuate with market performance
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 15.65b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 2.81 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.04 > 3% & CFO 28.20b > Net Income 15.65b |
| Net Debt (38.24b) to EBITDA (15.78b): 2.42 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (2.03b) vs 12m ago -8.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 27.51% > 50% (prev 29.03%; Δ -1.52% > 0%) |
| Interest Coverage Ratio: 11.68 > 6 (EBITDA TTM 15.78b / Interest Expense TTM 906.0m) |
Altman Z''
| A: error (Total Current Assets 319.95b - Total Current Liabilities none) / Total Assets 635.54b |
| B: 0.07 (Retained Earnings 41.41b / Total Assets 635.54b) |
| C: 0.02 (EBIT TTM 10.59b / Avg Total Assets 639.99b) |
| D: 0.07 (Book Value of Equity 41.41b / Total Liabilities 585.98b) |
Beneish M
| DSRI: none (Receivables none/9.90b, Revenue 176.09b/187.11b) |
| GMI: 1.01 (GM 101.1% / 102.4%) |
| AQI: 0.66 (AQ_t 0.49 / AQ_t-1 0.75) |
| SGI: 0.94 (Revenue 176.09b / 187.11b) |
| TATA: -0.02 (NI 15.65b - CFO 28.20b) / TA 635.54b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of CS shares?
As of March 28, 2026, the stock is trading at EUR 37.90 with a total of 4,129,238 shares traded.
Over the past week, the price has changed by -1.40%, over one month by -7.24%, over three months by -7.24% and over the past year by -0.33%.
Over the past week, the price has changed by -1.40%, over one month by -7.24%, over three months by -7.24% and over the past year by -0.33%.
Is CS a buy, sell or hold?
AXA has no consensus analysts rating.
What are the forecasts/targets for the CS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.1 | 21.5% |
| Analysts Target Price | - | - |
CS Fundamental Data Overview March 25, 2026
Market Cap USD = 91.54b (79.17b EUR * 1.1562 EUR.USD)
P/E Trailing = 11.0731
P/E Forward = 9.1075
P/S = 0.8361
P/B = 1.7326
P/EG = 1.2526
Revenue TTM = 176.09b EUR
EBIT TTM = 10.59b EUR
EBITDA TTM = 15.78b EUR
Long Term Debt = 60.49b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 65.32b EUR (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 38.24b EUR (from netDebt column, last quarter)
Enterprise Value = 122.24b EUR (79.17b + Debt 65.32b - CCE 22.25b)
Interest Coverage Ratio = 11.68 (Ebit TTM 10.59b / Interest Expense TTM 906.0m)
EV/FCF = 4.48x (Enterprise Value 122.24b / FCF TTM 27.26b)
FCF Yield = 22.30% (FCF TTM 27.26b / Enterprise Value 122.24b)
FCF Margin = 15.48% (FCF TTM 27.26b / Revenue TTM 176.09b)
Net Margin = 8.89% (Net Income TTM 15.65b / Revenue TTM 176.09b)
Gross Margin = unknown ((Revenue TTM 176.09b - Cost of Revenue TTM -1.90b) / Revenue TTM)
Tobins Q-Ratio = 0.19 (Enterprise Value 122.24b / Total Assets 635.54b)
Interest Expense / Debt = 0.46% (Interest Expense 299.0m / Debt 65.32b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 7.94b (EBIT 10.59b * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets 319.95b / Total Current Liabilities none)
Debt / Equity = 1.38 (Debt 65.32b / totalStockholderEquity, last quarter 47.17b)
Debt / EBITDA = 2.42 (Net Debt 38.24b / EBITDA 15.78b)
Debt / FCF = 1.40 (Net Debt 38.24b / FCF TTM 27.26b)
Total Stockholder Equity = 46.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.44% (Net Income 15.65b / Total Assets 635.54b)
RoE = 34.00% (Net Income TTM 15.65b / Total Stockholder Equity 46.03b)
RoCE = 9.94% (EBIT 10.59b / Capital Employed (Equity 46.03b + L.T.Debt 60.49b))
RoIC = 6.90% (NOPAT 7.94b / Invested Capital 115.00b)
WACC = 3.51% (E(79.17b)/V(144.49b) * Re(6.12%) + D(65.32b)/V(144.49b) * Rd(0.46%) * (1-Tc(0.25)))
Discount Rate = 6.12% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -4.59%
[DCF] Terminal Value 87.64% ; FCFF base≈20.15b ; Y1≈23.25b ; Y5≈32.80b
[DCF] Fair Price = 441.1 (EV 960.32b - Net Debt 38.24b = Equity 922.07b / Shares 2.09b; r=6.0% [WACC]; 5y FCF grow 17.97% → 3.0% )
EPS Correlation: -4.58 | EPS CAGR: -58.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: 5.03 | Revenue CAGR: 36.44% | SUE: 0.22 | # QB: 0
EPS current Year (2026-12-31): EPS=4.13 | Chg7d=-0.019 | Chg30d=-0.023 | Revisions Net=+4 | Growth EPS=+6.9% | Growth Revenue=+25.1%
EPS next Year (2027-12-31): EPS=4.45 | Chg7d=+0.008 | Chg30d=+0.009 | Revisions Net=+3 | Growth EPS=+7.7% | Growth Revenue=+4.5%
[Analyst] Revisions Ratio: +0.50 (6 Up / 2 Down within 30d for Current Year)
[Growth] Implied Growth Rate = -1.1% (Discount Rate 7.9% - Earnings Yield 9.0%)
[Growth] Growth Spread = +5.6% (Analyst 4.5% - Implied -1.1%)
P/E Trailing = 11.0731
P/E Forward = 9.1075
P/S = 0.8361
P/B = 1.7326
P/EG = 1.2526
Revenue TTM = 176.09b EUR
EBIT TTM = 10.59b EUR
EBITDA TTM = 15.78b EUR
Long Term Debt = 60.49b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 65.32b EUR (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 38.24b EUR (from netDebt column, last quarter)
Enterprise Value = 122.24b EUR (79.17b + Debt 65.32b - CCE 22.25b)
Interest Coverage Ratio = 11.68 (Ebit TTM 10.59b / Interest Expense TTM 906.0m)
EV/FCF = 4.48x (Enterprise Value 122.24b / FCF TTM 27.26b)
FCF Yield = 22.30% (FCF TTM 27.26b / Enterprise Value 122.24b)
FCF Margin = 15.48% (FCF TTM 27.26b / Revenue TTM 176.09b)
Net Margin = 8.89% (Net Income TTM 15.65b / Revenue TTM 176.09b)
Gross Margin = unknown ((Revenue TTM 176.09b - Cost of Revenue TTM -1.90b) / Revenue TTM)
Tobins Q-Ratio = 0.19 (Enterprise Value 122.24b / Total Assets 635.54b)
Interest Expense / Debt = 0.46% (Interest Expense 299.0m / Debt 65.32b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 7.94b (EBIT 10.59b * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets 319.95b / Total Current Liabilities none)
Debt / Equity = 1.38 (Debt 65.32b / totalStockholderEquity, last quarter 47.17b)
Debt / EBITDA = 2.42 (Net Debt 38.24b / EBITDA 15.78b)
Debt / FCF = 1.40 (Net Debt 38.24b / FCF TTM 27.26b)
Total Stockholder Equity = 46.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.44% (Net Income 15.65b / Total Assets 635.54b)
RoE = 34.00% (Net Income TTM 15.65b / Total Stockholder Equity 46.03b)
RoCE = 9.94% (EBIT 10.59b / Capital Employed (Equity 46.03b + L.T.Debt 60.49b))
RoIC = 6.90% (NOPAT 7.94b / Invested Capital 115.00b)
WACC = 3.51% (E(79.17b)/V(144.49b) * Re(6.12%) + D(65.32b)/V(144.49b) * Rd(0.46%) * (1-Tc(0.25)))
Discount Rate = 6.12% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -4.59%
[DCF] Terminal Value 87.64% ; FCFF base≈20.15b ; Y1≈23.25b ; Y5≈32.80b
[DCF] Fair Price = 441.1 (EV 960.32b - Net Debt 38.24b = Equity 922.07b / Shares 2.09b; r=6.0% [WACC]; 5y FCF grow 17.97% → 3.0% )
EPS Correlation: -4.58 | EPS CAGR: -58.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: 5.03 | Revenue CAGR: 36.44% | SUE: 0.22 | # QB: 0
EPS current Year (2026-12-31): EPS=4.13 | Chg7d=-0.019 | Chg30d=-0.023 | Revisions Net=+4 | Growth EPS=+6.9% | Growth Revenue=+25.1%
EPS next Year (2027-12-31): EPS=4.45 | Chg7d=+0.008 | Chg30d=+0.009 | Revisions Net=+3 | Growth EPS=+7.7% | Growth Revenue=+4.5%
[Analyst] Revisions Ratio: +0.50 (6 Up / 2 Down within 30d for Current Year)
[Growth] Implied Growth Rate = -1.1% (Discount Rate 7.9% - Earnings Yield 9.0%)
[Growth] Growth Spread = +5.6% (Analyst 4.5% - Implied -1.1%)